Zymeworks Inc. (ZYME)
NASDAQ: ZYMEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ZYME stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.81B
- P/E (TTM)
- 49.32
- Forward P/E
- 54.95
- EPS (TTM)
- $0.53
- Dividend yield
- None
- 52-week range
- 21.52 – 31.97
- Day range
- 26.09 – 27.56
- Volume / Avg
- 738.81K / 1.09M
- Beta
- —
- Shares outstanding
- 68.70M
52-week range
ZYME stock today
On Nov 20, ZYME ended the session at $26.14, shedding $0.72 (2.68%), versus the S&P 500's 3.70% decline. Shares are 18.2% below their 52-week high of $31.97, set on Nov 10, 2026 and 21.5% above the 52-week low of $21.52, in the middle of the past year's range. ZYME is down 0.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.8%.
Zymeworks trades at 49.3x its trailing twelve-month earnings per share of $0.53. Its forward P/E of 55.0x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Zymeworks
Company profileZymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Kenneth H. Galbraith C.A.
- Headquarters
- Middletown, DE
- Employees
- 279
- Website
- zymeworks.com
Financial highlights
Full financialsIn fiscal 2025, Zymeworks generated $106.0 million in revenue, up 38.9% from fiscal 2024, its 2nd consecutive year of revenue growth. Zymeworks reported a net loss of $81.1 million, compared with a loss of $122.7 million a year earlier. Operating margin was -87.3%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $105.97M | $76.30M | $76.01M | $412.48M | $26.68M |
| Growth | +38.87% | +0.38% | -81.57% | +1446.03% | -31.50% |
| Net income | $-81.13M | $-122.69M | $-118.67M | $124.34M | $-211.84M |
| EPS (diluted) | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$43.29+65.61%
- Strong buy 2
- Buy 12
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.26 vs $2.40
- Surprise
- -110.83%
ZYME news
All ZYME news- Zymeworks Announces Participation in Upcoming Investor ConferencesGlobeNewswire
- Zymeworks Authorized To Buy Back Up To $200 Mln Of SharesNasdaq
- Zymeworks authorizes up to $200M in share repurchasesSeeking Alpha
- Zymeworks Announces $200 Million Share Repurchase AuthorizationGlobeNewswire
- Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- Zymeworks early-stage results on ADC show anti-tumor activity in ovarian cancerSeeking Alpha
- Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026GlobeNewswire
- Why is Zymeworks stock surging today?Investing.com
Zymeworks peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MRVIMaravai LifeSciences Holdings Inc. Class A | 6.98 | -2.92% | $1.81B | vs ZYME |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs ZYME |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs ZYME |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs ZYME |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs ZYME |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs ZYME |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs ZYME |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs ZYME |
Indexes, lists and sector
Zymeworks stock FAQ
What is Zymeworks's stock price today?
ZYME last traded at $26.14 as of Nov 20, 4:00 PM EST, down 2.68% on the day. Prices are delayed at least 15 minutes.
What is ZYME's P/E ratio?
ZYME trades at a trailing P/E ratio of 49.32 and a forward P/E of 54.95.
Who is Zymeworks's CEO?
Mr. Kenneth H. Galbraith C.A. is the chief executive officer of Zymeworks Inc., which has about 279 employees.
What is the ZYME 52-week high?
The 52-week high for ZYME is $31.97 and the 52-week low is $21.52. The stock is currently 18.2% below its high.